Half of patients who die from prostate cancer have metastases at diagnosis
the ONA take:
According to a new study published in the journal Prostate Cancer & Prostatic Diseases, researchers sought to determine which types of patients die from prostate cancer in the modern era.
The researchers identified 190 men with metastatic castration-resistant prostate cancer (CRPC) treated between 2008 and 2011 and analyzed the characteristics of the 113 patients who died as a result of prostate cancer.
Of the 113 patients, 56% had identifiable metastases at the time of diagnosis. Of those, 67% had bone metastases, 111% had visceral metastases, and 43% had lymph node metastases. The median time to developing CRPC was 16 months and the median overall survival was approximately 5.2 years.
Among patients who died from prostate cancer, 46% of those initially diagnosed with localized disease had T stage ≥3 and 38% had a Gleason score ≥8. Overall, 26% had a Gleason score ≤6 and 64% were classified as having high-risk prostate cancer. The median overall survival was found to be 8.8 years.
The findings suggest that among those who die from prostate cancer, about half have detectable metastases at diagnosis. Therefore, the researchers recommend that more future studies should be conducted in patients with newly diagnosed metastatic prostate cancer.
researchers sought to determine which types of patients die from prostate cancer in the modern era.
The authors used two monthly curated databases of patients with castration–resistant prostate cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era. In the modern era, approximately half of the patients who die from CaP have metastases at diagnosis.
The paradigm of progression from localized disease to metastasis and eventually death is only represented in the other half, although possible initial screening and staging errors ought to be taken into consideration. More efforts are needed to conduct trials in patients with newly diagnosed metastatic CaP.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|